2018

Induction chemotherapy (CT) with FOLFIRINOX or FOLFOX/FOLFIRI, plus cetuximab (CET) or bevacizumab (BEV) (by RAS status), in patients (pts) with primarily unresectable colorectal liver metastases (CRLM): Results of the randomized UNICANCER PRODIGE 14-ACCO

Congress : ASCO

Authors : M. Ychou,  M. Rivoire, S. Thezenas, R.Guimbaud, F. Ghiringhelli, A. Mercier Blas, L. Mineur, E. Francois, F. Khemissa, M. Chauvenet, Y. Becouarn, P. Houyau, T. Aparicio,  M.P. Galais, F. Audemar, E. Assenat, A. Adenis, C. Jouffroy-Zeller, R. Adam, O. Bouche

Experts group or program : Groupe gastro-intestinal (UCGI)

 

pts with unresectable CRLM who respond to induction CT allowing curative-intent liver surgery have longer overall survival (OS) than pts who do not. Triplet (3-) or doublets (2-) CT, combined with CET or BEV, are often used in this setting. However, the best CT regimen remains to be determined.

 

En savoir plus